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Abstract
Background: Cardiac surgery with cardiopulmonary bypass (CS/CPB) is associated with increased risk for postoperative
complications causing substantial morbidity and mortality. To identify the molecular mechanisms underlying CS/CPB-
induced pathophysiology we employed an integrative systems biology approach using the whole blood transcriptome as
the sentinel organ.
Methodology/Principal Findings: Total RNA was isolated and globin mRNA depleted from whole blood samples
prospectively collected from 10 patients at time points prior (0), 2 and 24 hours following CS/CPB. Genome-wide
transcriptional analysis revealed differential expression of 610 genes after CS/CPB (p,0.01). Among the 375 CS/CPB-
upregulated genes, we found a gene-regulatory network consisting of 50 genes, reminiscent of activation of a coordinated
genetic program triggered by CS/CPB. Intriguingly, the highly connected hub nodes of the identified network included key
sensors of ischemia-reperfusion (HIF-1alpha and C/EBPbeta). Activation of this network initiated a concerted inflammatory
response via upregulation of TLR-4/5, IL1R2/IL1RAP, IL6, IL18/IL18R1/IL18RAP, MMP9, HGF/HGFR, CalgranulinA/B, and
coagulation factors F5/F12 among others. Differential regulation of 13 candidate genes including novel, not hitherto CS/
CBP-associated genes, such as PTX3, PGK1 and Resistin, was confirmed using real-time quantitative RT-PCR. In support of
the mRNA data, differential expression of MMP9, MIP1alpha and MIP1beta plasma proteins was further confirmed in 34
additional patients.
Conclusions: Analysis of blood transcriptome uncovered critical signaling pathways governing the CS/CPB-induced
pathophysiology. The molecular signaling underlying ischemia reperfusion and inflammatory response is highly intertwined
and includes pro-inflammatory as well as cardioprotective elements. The herein identified candidate genes and pathways
may provide promising prognostic biomarker and therapeutic targets.
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Introduction
Cardiac surgery including coronary artery bypass grafting
(CABG) and valvular replacement or repair are among the most
frequently performed life-saving surgical procedures. Since the
introduction of cardiopulmonary bypass (CPB) in the 1950s,
extracorporeal circulation became an integral component of
cardiac surgery [1]. Despite continuous technical improvements,
cardiac surgery with CPB (CS/CPB) provokes tissue ischemia-
reperfusion injury and a vigorous systemic inflammatory response
that may ultimately lead to the development of postoperative
complications [2,3]. A frequent complication of this CS/CPB-
induced systemic inflammatory response syndrome (SIRS) is the
development of organ dysfunction, including the lungs and kidneys
[4,5]. It has been reported that 20% of ‘‘low risk’’ patients who
undergo CS/CPB may develop postoperative complications [6]
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(MODS) was 11% with mortality rates of 41% for this group of
patients [7]. Despite these morbidity and mortality rates little is
known about the molecular mechanisms underlying the patho-
physiology of CS/CPB-induced postoperative complications.
The surgical trauma, blood loss, transfusion of blood products
and hypothermia were discussed as non specific stimulants of the
cardiac surgery-induced inflammatory response [8]. However, the
CS/CPB-induced pathophysiology appears to be a composite of at
least two distinct mechanisms that specifically contribute to the
inflammatory response. First as a result of the aortic cross-
clamping, unstable peri-bypass hemodynamics, global myocardial
ischemia and suboptimal organ perfusion during CPB ischemia–
reperfusion injury may occur in various organs, including the
brain, heart, lung, kidney, intestine and liver. A second critical
component of the immune response might be the direct ‘‘contact
activation’’ (priming) of the circulating blood leukocytes via
exposure to the foreign surfaces of the extracorporeal CPB circuit
[8–19].
Research in this area has thus far focused predominantly on
quantifying and correlating the levels of pertinent circulating
inflammatory proteins with exposure to the CS/CPB event or with
clinical outcomes. Further, differential regulation of genes and
proteins in ischemic organs as well as in the blood during the
ischemia-reperfusion process have been studied [20–22]. These
studies were focused on identifying differential regulation of genes
during CS/CPB as a function of disease states, e.g. vascular
permeability in patients with diabetes mellitus, or in association
with clinical outcomes such as neurocognitive decline or atrial
fibrillation. These correlative data have improved our understand-
ing of the CS/CPB-induced inflammatory response. Nonetheless,
a systematic and integrative analysis of the molecular mechanisms
underlying the initiation and execution of the inflammatory
response following CS/CPB is still needed.
In contrast to previous approaches as outlined above, we sought
to investigate the circulating blood cell transcriptome as a sentinel
organ that is exposed to both incriminated mechanisms, direct
contact activation via the extracorporeal membrane of the CPB
circuit as well as ischemia-reperfusion mechanisms occurring in
the heart, lungs and other organs during cardiac surgery. We
hypothesized that the exposure of circulating blood cells, including
leukocytes and leukocyte progenitor cells, to these stimuli will
result in a perturbation of their transcriptome enabling the
detection of the sensing event and the molecular signaling that
governs the CS/CPB-induced systemic inflammatory response.
Methods
Study design and patient selection
This is an ancillary prospective cohort study conducted between
February 2006 and January 2007 at St. Elizabeth’s Medical
Center in Boston, MA, as part of an ongoing parent study aimed
at evaluating genetic risk markers for acute kidney injury following
cardiac surgery. All consecutive adult subjects (age 18 years or
greater) scheduled to undergo on-pump cardiac surgery were
eligible for enrollment. Exclusion criteria were age under 18 years,
off-pump surgery, pregnancy, long-term or acute dialysis, and
organ transplantation within the prior year. Written informed
consent was obtained from all study participants or next of kin.
The Research/Human Subjects Committee of the institutional
review board at St. Elizabeth’s Medical Center approved the study
protocol, and the study was conducted in accordance with the
ethical standards laid down in the Declaration of Helsinki of 1975,
as revised in 1983.
For the purpose of the whole blood genome-wide transcriptional
analysis, out of the parent study, we selected ten patients sharing
similar pre-operative clinical characteristics including age, preop-
erative serum creatinine, left ventricular ejection fraction,
inclusion of valvular surgery and CPB perfusion time.
For the purpose of plasma protein analyses, as a confirmatory
selected gene product analysis, 34 additional patients undergoing
cardiac surgery were identified from the parent study.
Data collection
Medical records of study participants were reviewed prospec-
tively to retrieve pre-operative variables including baseline
demographic characteristics, coexisting conditions, intraoperative
variables including CPB time, cross-clamp time, surgery type, and
post-operative variables including serial serum creatinine values
and hospital outcomes.
Blood sampling
For peripheral blood RNA sampling, venous whole blood was
collected immediately before, and 2 and 24 hours following CPB
into PAXgene Blood RNA collection tubes (PreAnalytiX GmbH,
Hombrechtikon, CH), which were initially stored at 220uC until
extraction, and then stored at 280uC.
For plasma protein analysis, EDTA-anticoagulated blood was
collected immediately before and at 2, 24 and 48 hours following
CPB. Samples were kept on ice and processed within 30 minutes
of collection. Plasma was separated immediately by double
centrifugation at 3000 RPM for 5 minutes and 10,000 RPM for
another 5 minutes, to remove platelets, each at +4uC. Plasma was
immediately transferred and the samples stored at 280uC.
RNA isolation, globin mRNA depletion, and RNA integrity
assessment
Whole blood total RNA was extracted using the PAXgene
blood RNA extraction kit (Qiagen, Hilden, Germany). Globin
mRNA is expressed at high levels in erythrocytes and reticulocytes,
and up to 70% of the mRNA in whole blood total RNA consists of
globin transcripts, which decreases the sensitivity of blood-based
expression profiling techniques for detecting less abundant
mRNAs [20–23]. This reduced sensitivity might have limited
previous whole blood transcriptomic approaches to detect low-
copy number genes, e.g. using inflammatory genes tailored
microarrays [24]. To enhance the overall sensitivity of the
expression profiling platform and to detect low-abundance
mRNAs, a and b globin mRNAs were depleted from total RNA
by selective hybridization and magnetic bead separation method,
using the GLOBINclear Kit (Ambion, Austin, TX). The RNA
quality was assured after both Paxgene total-RNA isolation and
globin mRNA depletion by assessing the 18S/28S ratio and RNA-
integrity (RIN) scores. RNA integrity was assessed by lab-on chip
technology, using the Agilent 2100 bioanalyzer, in combination
with the RNA 6000 Lab Chip kit (Agilent Technologies,
Boeblingen, Germany). All kits were used according to the
manufacturer’s instructions. RNA quantity was measured using
the NanoDrop
TM Spectrophotometer (Thermo Scientific, Wal-
tham, MA).
Genome-wide expression profiling
Genome- wide expression profiling was performed using whole
human genome 4x44k oligo microarrays (Agilent, G4112F). Linear
amplification from 500 ng of total RNA and spike-in-controls
(Agilent #5188–5282) was performed using the Agilent low RNA
Input Linear Amplification Kit Plus, one color (#5188–5339). During this
Transcriptome in Heart Surgery
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incorporation of fluorescently labelled nucleotides into the
amplified RNA. Labelled probes were purified with RNeasy mini
spin columns (Qiagen #74104). Cy3- labelled probe and blocking
agent were combined for chemical fragmentation of the probe
molecules. Fragmentation was stopped by adding 55 ml 2x GEx
hybridisation buffer HI-RPM leading to a final volume of 110 ml
(Gene expression hybridization kit, Agilent #5188–5242). Chip
hybridization was performed using the gasket/slide-sandwich
system and the hybridisation chamber (Agilent, #G2534A)
according to manufacturer instructions. During hybridisation
slides were rotated at 10 rpm and 65uC for 16 h. Microarray
slides were washed 1 min in GE Wash Buffer 1 (Agilent, #5188–
5326) at room temperature, 1 min in GE Wash Buffer 2 (Agilent,
#5188–5326) at room temperature and 30s in Acetonitril at room
temperature on a magnetic stirrer. Microarray slides were scanned
in an Agilent Microarray Scanner and analysis of the resulting
array images was performed using the Feature Extraction software
(Agilent, Version 9.1). Microarray data were stored in the MO-
MEX database Bloader, which enables direct submission of large
batches of MIAME compliant expression profiling data to the
ArrayExpress database. Microarray data are available online at
ArrayExpress (http://www.ebi.ac.uk/arrayexpress), under the
accession number E-TABM-595.
Microarray data analysis
Generation of expression matrices, data annotation, filtering
and processing were performed as described previously using the
TableButler software package (http://www.OncoExpress.org/
software/tablebutler) [25,26]. All microarray statistics including
t-test and analysis of variance (ANOVA) with permutation analysis
(n=1000) and cluster analysis were performed using the SUMO
software package [25–27]. Pathway analysis was performed based
on information available on cellular signaling processes (e.g.
protein-protein interaction, geneontology, involvement in specific
signaling pathway etc.) using a curated database on signaling
networks and systems biology package (MetacoreH, Genego, www.
genego.com). The metacore manually annotated database was
derived from literature publications on proteins and small
molecules (MetaCore
TM, GeneGo, St. Joseph, MI). This was
developed with an Oracle version 9.2.0.4 Standard Edition
(Oracle, Redwood Shores, CA) based-architecture for the
representation of biological functionality and integration of
functional, molecular, or clinical information. To construct the
network, we searched and analyzed direct interactions among the
CPB-induced genes in the whole blood transcriptome.
Real-time quantitative RT-PCR
Expression levels of RNA transcripts were quantitated by the
ABI 7300 real time PCR system (Applied Biosystems, Foster City,
CA) as previously described [25,28,29]. After RNA isolation, first
strand cDNA was reverse transcribed from total RNA using the
cDNA Archive Kit (MultiScribe Reverse Transcriptase, Applied
Biosystems) and stored at 220uC until use. Complementary DNAs
were mixed with PCR master mix and primers (Applied
Biosystems), and real-time PCR was performed. TaqManH
primers and probes information is listed in Appendix S1.
In addition to profiling all samples for the target sequence,
samples were profiled for 18S ribosomal RNA expression as an
endogenous control. For low copy number genes, b macroglobulin
was used as an alternative endogenous control. For each single
well amplification reaction, a threshold cycle was observed in the
exponential phase of amplification and the quantitation of relative
expression levels was achieved using standard curves for both the
target and endogenous controls.
Plasma protein analyses
Plasma levels of three representative proteins, matrix metallo-
proteinase-9 (MMP-9), macrophage inflammatory protein-1 alpha
(MIP-1a) and macrophage inflammatory protein-1 beta (MIP-1b),
found to be upregulated by genome-wide expression profiling,
were measured by the Luminex microbeads technique (Linco Inc.,
St. Louis, MO). In brief, 25 ml of sample, standard solutions or
quality control samples were added to each well of a 96-well plate
with 25 ml of the bead solution. The plate was incubated overnight
on a plate shaker at 4uC, washed twice with 200 ml each of wash
buffer, removing buffer by vacuum filtration between each wash,
followed by addition of 25 ml of a detection antibody cocktail and
incubated at room temperature for 1.5 h. After adding 25 mlo fa
streptavidin-phycoerythrin solution to each well and incubating at
room temperature for 30 min, the plates were then analyzed on
the LuminexIS100 analyzer (Luminex Inc., Austin TX). The data
were evaluated as Median Fluorescence Intensity (MFI) using
appropriate curve-fitting software (Luminex 100IS software
version 2.3). All measurements were performed in duplicate.
Analyses were performed in duplicates and the responsible
investigators (Francesco Adabbo, PhD and Michael Goligorksy,
MD, PhD) were blinded to the results of the genome-wide
expression profiling and RT-PCR.
Statistical analyses
Continuous variables are presented as means (6 standard
deviation), and categorical variables as frequencies. For the
microarray data, clustering and statistical analysis were performed
using SUMO and Genego (metacore) software packages. Multiple
comparisons were performed using the Bonferroni method, and
differences were considered statistically significant at a P value of
less than 0.05.
For the plasma protein analysis, after log-transformation of the
data due to skewed distribution, Kruskal-Wallis test for change
over time was used to compare between 4 measurement time
points (pre-CPB, and 2-hour, 24-hour and 48-hour post-CPB).
These statistical analyses were performed using SAS software
(version 9.1; SAS Institute, Cary, NC). Differences were
considered statistically significant at a P value of less than 0.05.
Results
Characteristics of the cohort
The clinical characteristics of each of 10 study participants
selected to detect perturbations of the whole blood transcriptome
in response to cardiac surgery with CPB are shown in Table 1. In
brief, patients were predominantly male with a mean age of
70611 years, all of whom had hypertension. The left ventricular
function was preserved with a mean ejection fraction of 58610%,
and the kidney function was normal with a mean serum creatinine
of 0.9860.18 mg/dl. 50% of the patients underwent valvular
surgery, and CPB perfusion time averaged 121626 min.
Genome-wide transcriptional analysis
In total, 28 blood samples that passed the RNA quality criteria
(RIN.7) were hybridized against pan genomic (44K) oligo-
microarrays. Gene intensities were quintile and virtual pool
normalized. The expression ratios were lg2 transformed. Genes
with an average intensity of less than 10 over all samples were
removed. We found 6,351 transcripts to be differentially regulated
from the time point prior to CPB (0 hour) vs. 2 hours vs. 24 hours
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candidate CS/CPB-regulated genes, we applied multiple testing
correction, and identified 916 differentially regulated transcripts
(P,0.01, after standard Bonferroni correction). The 916 tran-
scripts represented 610 unique, i.e., known genes, among which
375 genes were upregulated, whereas 235 genes were downreg-
ulated after CS/CPB (Figure 1A). The selected sets of genes are
presented as a heatmap using hierarchical clustering (HCL) with
Euclidean distances and complete linkage analysis. A detailed list
of the significantly regulated genes is presented in supplemental
SOM Table S1. To identify the critical involvement of specific
functional gene categories in response to CS/CPB, we mapped the
610 CS/CPB-regulated genes to the corresponding gene ontologies
according to the information available on www.geneontology.org.
The top 10 significantly affected functional processes by CS/CPB
were selected and sorted based on the lowest p-values (Figure 1B).
We found an enrichment of functional gene categories related to
the immune system processes such as leukocyte activation and
differentiation, and cell survival/apoptosis signaling among the
CS/CPB regulated genes. These data demonstrate the feasibility
of whole blood transcriptome analysis to uncover the molec-
ular mechanisms underlying the inflammatory response evoked by
CS/CPB.
Identification of a CS/CPB–induced transcriptional
network
To analyze the microarray data in an integrative manner, we
searched for potential known interactions among the herein
identified CS/CPB-induced genes. Intriguingly, we found that a
substantial fraction of CS/CPB upregulated genes interact directly
with each other and constitute an intricate gene regulatory
network (Figure 2). Our data indicate that a coordinated genetic
program rather than single pathways governs the inflammatory
response evoked by the cardiac surgery with CPB. Interestingly,
the high degree or hub nodes of the network consisted of known key
hypoxia sensors such as the transcription factor hypoxia-inducible
factor 1 alpha (HIF1alpha) and CCAAT/Enhancer binding
protein (C/EBPbeta). Of note, the involvement of C/EBPbeta in
myocardial ischemia reperfusion injury was only recently de-
scribed in an experimental rat model [30]. The activation of C/
EBPbeta was attributed to the transcriptional upregulation of the
key proinflammatory protein interleukin 6 (IL-6). Our network
analysis revealed that in addition to IL-6, C/EBPbeta is directly
regulating at least 15 other CS/CPB-induced genes, including
prominent inflammatory response elements such as Calgranulin A
and B (also known as Leukocyte L1 antigen complex) or Resistin.
Conclusively, the network analysis connects mechanisms of
ischemia-reperfusion injury with systemic inflammatory response
mechanisms, and suggests a key role for tissue ischemia in direct
upregulation of a plethora of inflammatory associated genes such
as matrix metallaproteinases (MMP9), and Toll-like receptors
(TLR4/5). We also found four members of the interleukin 1 (IL-1)
receptor family, i.e., IL-1 receptor 2 (IL-1R2), IL-1 receptor
associated protein (IL-1RAP), IL-18R1 and IL-18RAP, to be
upregulated in response to CS/CPB (box in Figure 2).
Confirmatory real time quantitative RT PCR analysis
To confirm the differential regulation pattern of genes observed
by microarray analysis after CS/CPB, we selected 13 genes for
confirmation analysis by real time quantitative RT-PCR (qPCR).
Relative expression levels of genes (compared to the pre-CPB time
point) are presented in Figures 3 and 4. The regulation of both hub
nodes of the CS/CPB–induced network, HIF1alpha and C/
EBPbeta, was confirmed by qPCR. Both genes were consistently
upregulated in all patients with a maximum peak 2 hours post-
CPB. The expression of their downstream network targets such as
the Hepatocyte Growth Factor/Receptor pair (HGF/HGFR),
Toll-like receptor 4 (TLR4), Resistin and MMP9, was also
confirmed. From the IL-1 receptor family, the CS/CPB–induced
enhanced expression of IL-18R1 and its ligand IL-18 was
detected. Further, the expression of four genes that were
significantly upregulated after CS/CPB in the microarray analysis
(P,0.01, supplemental SOM Table S1) but not included in the
direct interaction network, was also confirmed by qPCR. These
included genes involved in oxidative stress response, such as
Glyceraldehyde-3 Phosphate Dehydrogenase (GAPDH), novel
early predictors of organ dysfunction, e.g. Lipocalin 2 (LCN2, also
known as NGAL) and glucose metabolizing enzyme phosphoglyc-
erate kinase 1 (PGK1), and a novel gene that is proposed to exert
potent cardioprotective effects, Pentraxin 3 (PTX3).
Confirmatory serum protein analysis
To confirm the differential regulation pattern of genes on
protein level, plasma samples of 34 additional patients undergoing
on-pump cardiac surgery were analyzed. Subjects in this group
had a mean age of 72611 years, a left ventricular ejection fraction
of 51615%, a preoperative serum creatinine of 1.160.3 mg/dl,
and underwent CPB perfusion for 132642 minutes. 75% were
Table 1. Clinical characteristics of the study cohort.
Patient ID 244 246 247 252 253 259 261 262 268 271
Age (years) 61 69 82 79 62 74 53 57 80 80
Sex M M M M F M M M M M
Hypertension Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Chronic lung disease No No Yes No No No Yes No Yes No
Congestive heart failure No No No No Yes No No No No Yes
Diabetes mellitus No No No No Yes No No No No No
Left ventricular ejection fraction (%) ND 55 65 55 ND 65 35 65 60 60
Baseline serum creatinine (mg/dl) 1.0 1.0 0.8 0.9 1.4 1.0 0.9 1.1 0.9 0.8
Cardiopulmonary bypass time (min) 85 174 98 120 137 134 98 104 133 127
Valve surgery No No Aortic Mitral Aortic No No No Aortic Aortic
ND denotes not determined.
doi:10.1371/journal.pone.0013658.t001
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2 h and 24 h post CPB revealed 916 differentially regulated transcripts corresponding to 610 known genes (p,0.01). The selected sets of genes are
presented as a heatmap using hierarchical clustering (HCL) with Euclidean distances and complete linkage analysis (for a detailed gene list see
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we detected a CS/CPB and time dependent increase in MMP9,
MIP1a and MIP1b protein levels (Figure 5). While plasma MIP1a
demonstrated a linear increase over time post-CPB, both MMP9
and MIP1b reached their maximum concentration 2 hours post-
CPB. Together, these data indicate that the regulation of genes
detected by whole blood transcriptomics was translated in
differential expression of the corresponding proteins in circulating
blood.
Discussion
Our data indicate that blood cells, including circulating
leukocytes and bone marrow derived progenitor cells, are dynamic
participants in the pathophysiology of CS/CPB-induced host
inflammatory response. Using circulating blood cells and their
transcriptome as the sentinel organ, we have devised a novel
strategy to decipher the molecular mechanisms underlying CS/
CPB–induced tissue ischemia-reperfusion injury and systemic
inflammatory response. In contrast to plasma or serum protein
profiles that provide associative rather than causative information
(e.g. potential stimuli or the source of the secreted proteins remain
undetermined), the whole blood transcriptomics provided a
unique opportunity to causally link the transcriptional perturba-
tion induced by exposure of circulating leukocytes to tissue
ischemia or the extracorporeal CPB membrane with the execution
of the inflammatory response.
The microarray data were rigorously validated by confirming
the differential mRNA expression of 13 CS/CPB-induced genes
by real time quantitative RT-PCR. To demonstrate that the
Figure 2. CS/CPB-induced gene regulatory network. A substantial fraction of CS/CPB-induced genes including both hypoxia and inflammatory
related genes are directly connected and constitute an intricate transcriptional network. Network analysis reveals a critical role for hypoxia sensors
HIF1alpha and c/EBPbeta in CS/CPB response. These data suggest that gene regulatory networks rather than single pathways govern the hypoxia-
and immune-modulatory effects triggered by CS/CPB. Four members of IL1 receptor family were also upregulated after CS/CPB (small box).
doi:10.1371/journal.pone.0013658.g002
supplemental SOM table S1). Each row represents lg2 expression ratios of an individual gene (CS/CPB vs. average intensity of all measurements) and
the columns indicate each respective patient (i.e., sample time points). Expression ratios are colored according to the scale bar: green =
downregulation, red = upregulation. Representative CS/CPB-induced genes are highlighted in the red box. Selected CS/CPB-induced genes are
highlighted in the red box. Functional processes (Panel B). The top 10 functional processes affected by CS/CPB treatment are presented. Data
analysis among CS/CPB regulated genes from the selected gene set resulted in significant enrichment for gene ontology processes and cell survival
or death. Bars represent -log p-values representing the probability for the gene ontology mapping arising by chance.
doi:10.1371/journal.pone.0013658.g001
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protein levels, we confirmed the protein expression of three
candidate CS/CPB-induced genes, i.e., MMP9, MIP1a and
MIP1b in an independent cohort of 34 additional patients.
The advantage of our genome-wide transcriptional analysis over
single protein or tailored pathway specific approaches was to
further the ability of analyzing the data in an integrative manner
and to detect system level convergence of pathways that were
previously believed to be distinct. By applying this approach to
CS/CPB-induced genes in peripheral blood, we identified a gene-
regulatory network connecting the signals mediated by exposure of
circulating blood cells to ischemia and reperfusion in heart, lungs
as well as distant organs (e.g. HIF1apha) or priming of leukocytes
via the extracorporeal CPB circuit (e.g. TLR4) with signals that
execute and facilitate the systemic inflammatory response (e.g. IL-
6 or MMP9). Thus, the molecular signalling that underlies tissue
ischemia and the inflammatory response seem to be highly
intertwined. Intriguingly, the gene network analysis revealed a
hierarchy in the transcriptional response, with key sensors of tissue
hypoxia, such as HIF1alpha constituting the hub nodes connected
with a number of downstream pro- and anti-inflammatory, i.e.
survival genes. Our data indicate a critical role for tissue hypoxia as
the key stimulus for the inflammatory response after cardiac
surgery rather than other hitherto discussed mechanisms such as
contact activation via CPB circuit or endotoxin exposure.
Interestingly, Emani et al. also reported HIF1alpha upregula-
tion in peripheral blood transcriptome after CS/CPB. However,
in that report the induction of HIF1alpha was detected selectively
in patients with diabetes mellitus [22], an observation that is not
supported by our data. Whole blood transcriptomics have further
been employed to correlate gene regulation after CS/CPB with
brain injury and artrial fibrillation [20,21]. However, unsupervised
direct hierarchical clustering of CS/CPB signatures did not clearly
distinguish between patients with and without postoperative atrial
fibrillation [21]. In contrast to our approach, dilution of target
mRNA by the high content of globin mRNA (up to 70% of total
mRNA) often limited the detection of low copy number genes
leading to decreased sensitivity of the first generation whole blood
transcriptomics data. Another explanation for the sensitivity of our
approach to detect novel CS/CPB targets could be that we
selected a rather homogenous study population consisting of
predominantly elderly, hypertensive, and male individuals. This
may have prevented additional biases induced by CS/CPB
independent variables in microarray analyses.
In support of our data, Tomic et al. recently employed a 3.7 k
tailored inflammation and immune response gene microarray and
showed that key inflammatory cytokines (e.g. IL-6) and genes
known to be involved in priming leukocytes such as adhesion
molecules and toll-like receptors, were also upregulated following
off-pump CABG to a similar extent as after CS/CPB, but with
altered kinetics, i.e., with delayed onset [24]. These authors
postulated that the current concept of contact activation by the
extracorporeal CPB circuit and subsequent release of cytokines of
circulating leukocytes might be oversimplified. Emerging data
suggest that indeed the key components of the inflammatory
response are also activated after off-pump surgery [24,31–33].
However, since all participants in our study underwent CPB, we
are unable to estimate the contribution of CPB to the
inflammatory response observed following CS/CPB.
Intriguingly, we found a number of novel CS/CPB–induced
genes such as PTX3, Toll-like receptors and resistin that were only
recently linked to cardiac pathology, in particular myocardial
infarction. One plausible explanation for our finding might be the
transient cardiac ischemia that occurs during cardiac surgery with
CPB, which parallels the pathophysiology of myocardial infarction.
Of note, the multi-center study of the Perioperative Ischemia
Research Group reported that up to 25% of patients fulfilled
electrocardiogram, cardiac marker or autopsy criteria for myocar-
dial infarction after CABG [34]. Therefore, the CS/CPB-induced
pathways identified in the present report might have important
implications for a better understanding of the pathophysiology and
identification of novel biomarkers of other myocardial ischemia
related disorders such as myocardial infarction.
Pentraxin 3 was recently considered as a master crossroad of
innate immunity and the inflammatory response. Leukocytes (i.e.,
phagocytes) were described as the key source of this fluid-phase
pattern recognition receptor (PRR). This might be a plausible
explanation for the ability of our approach to detect this gene by
genome-wide analysis of circulating blood leukocytes. In alignment
with our data, PTX3 plasma concentrations were shown to be
increased in patients with acute myocardial infarction and were
therefore suggested as an early indicator for infarction and
irreversible injury of the myocyte in ischemic cardiomyopathy
[35]. Likewise, Suzuki et al. identified plasma PTX3 as a novel
independent predictor of the clinical outcome in patients with heart
failure [36]. Most recently, Salio et al. discovered a cardioprotective
function for PTX3 in acute myocardial infarction experimentally
induced by coronary artery ligation and reperfusion [37]. They
found greater than 30% increased myocardial damage in PTX3-
deficient vs. wild type mice, which was accompanied by enhanced
leukocyteinfiltration,no-reflow areas,complementC3deposition in
the lesions, and apoptosis of the cardiomyocytes, while the number
of capillaries were decreased. Most importantly, the substitution of
mice with exogenous PTX3 reversed the exacerbated heart damage
in the PTX3-deficient mice, hence a potential non-redundant
cardioprotective role for this protein. These recent studies suggest
unique functional properties of PTX3 in the pathogenesis of
cardiovascular diseases. Together with our data, PTX3 seems to be
a very promising therapeutic target and valuable biomarker for
cardiac pathophysiology.
We also found differential regulation of Toll-like receptors, more
specifically TLR4 and TLR6, another family of proteins that play a
key role in the innate immune system and like PTX3 belong to the
PRR. Unlike Pentraxin, TLR4 has been reported to serve a pro-
inflammatory role in murine myocardial ischemia-reperfusion injury.
TLR4-deficient mice sustained smaller infarctions and exhibited less
inflammation compared to wild type mice after myocardial ischemia-
reperfusion injury induced by 1 hour of coronary ligation followed by
24 hours of reperfusion [38]. This effect was assumed to be unrelated
to the microbial pathogen or endotoxin–induced TLR4 activation
[38]. These data are in alignment with our observations of elevated
TLR4 mRNA expression levels in circulating human blood cells after
CS/CPB and suggest a critical pro-inflammatory role for TLR4 in
contactactivationofleucocytesviatheextracorporealmembraneand
myocardial ischemia-reperfusion injury, in addition to its role in
innate immune response.
In addition, phosphoglycerate kinase 1 (PKG1) gene expression
in response to CS/CPB was found in our patients. The protein
Figure 3. Confirmatory RT PCR analysis of selected genes. Bar graphs show fold-increases in mRNA of one gene, named at the top of each
figure. Each respective time point is represented by a different color: blue for the pre CPB (0 h), red for the 2 hour post CPB and green for the 24 hour
post CBP time point.
doi:10.1371/journal.pone.0013658.g003
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conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. In
line with our data, induction of HIF1alpha appears to upregulate
PKG1 expression [39]. PKG1 in turn induces CXCR4 expression,
whose ligand, CXCL12, also known as stromal derived factor-1
(SDF-1), was shown to be induced by tissue hypoxia. The
Figure 4. Resistin, PTX3 and TLR4 mRNA expression levels. The mRNA expression level of CS/CPB -induced genes detected by real time qPCR
parallels the microarray data.
doi:10.1371/journal.pone.0013658.g004
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mechanisms following hypoxic tissue damage for example in brain
[40], heart [41] and kidney [42], including homing of pluripotent
regenerative stem cells to sites of ischemic tissue injury [43].
Therefore, activation of the HIF1alpha-PKG1 axis might describe
another possible mechanism for the regenerative tissue response
induced by CS/CPB. The CS/CPB-induced upregulation of
resistin in our patients also provides an interesting link between
ischemia reperfusion injury and the inflammatory response. In
2001, Steppan et al. discovered a hormone that was suggested to
link obesity with type 2 diabetes mellitus [44]. It was postulated
that this protein secreted by mouse adipocytes might confer
resistance to insulin and was therefore named resistin [44].
However, later studies in patients with renal disease found a
correlation between elevated blood resistin levels and inflammation
or decreased glomerular filtration rate but not with insulin
resistance [45]. Moreover, resistin was shown to be primarily
expressed in human inflammatory cells (in contrast to rodents) and
to disturb the function of polymorphonuclear leukocytes, e.g. via
impairment of their chemotactic movement, thus, contributing to
the pathologic immune response associated with chronic kidney
disease or diabetes mellitus [46,47]. These data support our
finding of elevated resistin mRNA expression in circulating blood
leukocytes. Recently, it was reported that resistin-induced proin-
flammatory effects on the vascular wall might be triggered by
hypoxia [48]. Hence differential regulation of resistin following CS/
CPB might provide another link between tissue ischemia and the
inflammatory response. In this context, high plasma resistin levels
were found to predict mortality in patients with acute myocardial
infarction and to worsen cardiac ischemia-reperfusion injury via
impaired contractile recovery during reperfusion [49,50]. Togeth-
er, the herein newly identified CS/CPB-induced genes such as
PTX3, Toll-like receptors and resistin may represent interesting
targets for the development of CS/CPB-related biomarkers and/
or therapeutic strategies.
We have recently shown that transcriptome analysis provides a
powerful tool to uncover the molecular participants of homeostatic
processes, such as angiogenic balance and the angiogenic switch
[26,27]. Integrative analysis of our whole blood transcriptomics
approach suggests that the pro-inflammatory response evoked by
cardiac surgery with CPB is also balanced by anti-inflammatory
and pro-survival response elements. For example among the three
abovementioned CS/CPB-induced pathways resistin and TLR4
exert pro-inflammatory effects whereas PTX3 exhibit cardiopro-
Figure 5. Plasma protein level confirmation. Plasma protein levels (pg/mL) of three CS/CPB –induced genes identified by genome -wide
expression profiling. Protein analysis confirmed the whole blood transcriptomics data. We found a time dependent upregulation of matrix
metalloproteinase-9 (MMP9) and macrophage inflammatory protein-1 a and b (MIP1a/b) after CS/CPB in an independent cohort of additional 34
patients undergoing on-pump cardiac surgery. Mean (standard error of the mean). * P values; Kruskal-Wallis test for change over time.
doi:10.1371/journal.pone.0013658.g005
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organs from ischemia reperfusion-induced injury. By contrast, an
imbalanced inflammatory response may herald the onset of the
SIRS and organ dysfunction. Whether the here identified genes
could assist clinicians to predict the inflammatory status of
individuals at risk or aid in development of novel strategies to
revert the systems imbalance by developing targeted therapies
remains to be elucidated in prospective studies.
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